232 related articles for article (PubMed ID: 19531451)
21. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
22. HER-2 status determination in breast carcinomas. A practical approach.
García-Caballero T; Menéndez MD; Vázquez-Boquete A; Gallego R; Forteza J; Fraga M
Histol Histopathol; 2006 Mar; 21(3):227-36. PubMed ID: 16372244
[TBL] [Abstract][Full Text] [Related]
23. Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing.
Hicks DG; Kulkarni S
Arch Pathol Lab Med; 2008 Jun; 132(6):1008-15. PubMed ID: 18517261
[TBL] [Abstract][Full Text] [Related]
24. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy.
Ross JS
Drug News Perspect; 2009 Mar; 22(2):93-106. PubMed ID: 19330168
[TBL] [Abstract][Full Text] [Related]
25. HER2--a discussion of testing approaches in the USA.
Thor A
Ann Oncol; 2001; 12 Suppl 1():S101-7. PubMed ID: 11521714
[TBL] [Abstract][Full Text] [Related]
26. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.
Diaz NM
Cancer Control; 2001; 8(5):415-8. PubMed ID: 11579337
[TBL] [Abstract][Full Text] [Related]
27. Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.
Paik S; Bryant J; Tan-Chiu E; Romond E; Hiller W; Park K; Brown A; Yothers G; Anderson S; Smith R; Wickerham DL; Wolmark N
J Natl Cancer Inst; 2002 Jun; 94(11):852-4. PubMed ID: 12048273
[TBL] [Abstract][Full Text] [Related]
28. [Internal quality control on HER2 status determination in breast cancers: Experience of a cancer center].
Ngo C; Laé M; Ratour J; Hamel F; Taris C; Caly M; Le Cunff A; Reyal F; Kirova Y; Pierga JY; Vincent-Salomon A
Bull Cancer; 2017; 104(7-8):608-617. PubMed ID: 28595742
[TBL] [Abstract][Full Text] [Related]
29. [HER2 gene amplification assay: is CISH an alternative to FISH?].
Denoux Y; Arnould L; Fiche M; Lannes B; Couturier J; Vincent-Salomon A; Penault-Llorca F; Antoine M; Balaton A; Baranzelli MC; Becette V; Bellocq JP; Bibeau F; Ettore F; Fridman V; Gnassia JP; Jacquemier J; MacGrogan G; Mathieu MC; Migeon C; Rigaud C; Roger P; Sigal-Zafrani B; Simony-Lafontaine J; Trassard M; Treilleux I; Verriele V; Voigt JJ;
Ann Pathol; 2003 Dec; 23(6):617-22. PubMed ID: 15094603
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of HER2 status: for the treatment of metastatic breast cancers by humanized anti-HER2 Monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab).
Umemura S; Sakamoto G; Sasano H; Tsuda H; Akiyama F; Kurosumi M; Tokuda Y; Watanabe T; Toi M; Hasegawa T; Osamura RY
Breast Cancer; 2001; 8(4):316-20. PubMed ID: 11791124
[TBL] [Abstract][Full Text] [Related]
31. [Assessment of HER2 status in breast cancer].
Penault-Llorca F; Cayre A
Bull Cancer; 2004 Dec; 91 Suppl 4():S211-5. PubMed ID: 15899610
[TBL] [Abstract][Full Text] [Related]
32. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.
Perez EA; Suman VJ; Davidson NE; Martino S; Kaufman PA; Lingle WL; Flynn PJ; Ingle JN; Visscher D; Jenkins RB
J Clin Oncol; 2006 Jul; 24(19):3032-8. PubMed ID: 16809727
[TBL] [Abstract][Full Text] [Related]
33. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.
Dybdal N; Leiberman G; Anderson S; McCune B; Bajamonde A; Cohen RL; Mass RD; Sanders C; Press MF
Breast Cancer Res Treat; 2005 Sep; 93(1):3-11. PubMed ID: 16184453
[TBL] [Abstract][Full Text] [Related]
34. Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy.
Chorn N
Oncol Nurs Forum; 2006 Nov; 33(2):265-72. PubMed ID: 16518442
[TBL] [Abstract][Full Text] [Related]
35. HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.
O'Malley FP; Thomson T; Julian J; Have C; Cosby R; Gelmon K; Andrulis I; Whelan T
Arch Pathol Lab Med; 2008 Jan; 132(1):61-5. PubMed ID: 18181675
[TBL] [Abstract][Full Text] [Related]
36. [Determination of HER2 by fluorescence in situ hybridization (FISH) in breast cancer. Experience of the Reference Laboratory of Lisbon].
André S; Tomás AR; Fonseca R
Acta Med Port; 2005; 18(6):417-22. PubMed ID: 16684481
[TBL] [Abstract][Full Text] [Related]
37. HER-2 testing in breast cancer using parallel tissue-based methods.
Yaziji H; Goldstein LC; Barry TS; Werling R; Hwang H; Ellis GK; Gralow JR; Livingston RB; Gown AM
JAMA; 2004 Apr; 291(16):1972-7. PubMed ID: 15113815
[TBL] [Abstract][Full Text] [Related]
38. HER2 testing and its predictive utility in anti-HER2 breast cancer therapy.
Advani PP; Crozier JA; Perez EA
Biomark Med; 2015; 9(1):35-49. PubMed ID: 25605454
[TBL] [Abstract][Full Text] [Related]
39. Current status of HER2 testing.
Di Leo A; Dowsett M; Horten B; Penault-Llorca F
Oncology; 2002; 63 Suppl 1():25-32. PubMed ID: 12422052
[TBL] [Abstract][Full Text] [Related]
40. Concordance between central and local laboratory HER2 testing from a community-based clinical study.
Reddy JC; Reimann JD; Anderson SM; Klein PM
Clin Breast Cancer; 2006 Jun; 7(2):153-7. PubMed ID: 16800975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]